Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arterra Bioscience SpAMIL:ARBS -0.33%77 Piotroski F-Score is 7 as of Jul. 18, 2026, which is at its 10-year median of 7.00. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued). Among 1,333 Biotechnology companies, Arterra Bioscience SpA ranks better than 96.85% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Arterra Bioscience SpA has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Arterra Bioscience SpA's Piotroski F-Score or its related term are showing as below:
MIL:ARBS'
s Piotroski F-Score Range Over the Past 10 Years
Min: 5 Med: 7 Max: 8
Current: 7
During the past 9 years, the highest Piotroski F-Score of Arterra Bioscience SpA was 8. The lowest was 5. And the median was 7.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Arterra Bioscience SpA Piotroski F-Score Related Terms
Arterra Bioscience SpA Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Arterra Bioscience SpA's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:ARBS vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Arterra Bioscience SpA's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arterra Bioscience SpA Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Arterra Bioscience SpA's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Arterra Bioscience SpA's current Net Income (TTM) was 2.01.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Arterra Bioscience SpA's current Cash Flow from Operations (TTM) was 1.99.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Arterra Bioscience SpA's return on assets of this year was 0.14967915. Arterra Bioscience SpA's return on assets of last year was 0.10649992.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Arterra Bioscience SpA's gearing of this year was 0.01193283. Arterra Bioscience SpA's gearing of last year was 0.0200339.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Arterra Bioscience SpA's current ratio of this year was 7.73809524. Arterra Bioscience SpA's current ratio of last year was 9.98907767.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Arterra Bioscience SpA's number of shares in issue this year was 6.514. Arterra Bioscience SpA's number of shares in issue last year was 6.514.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Arterra Bioscience SpA's gross margin of this year was 0.92731137. Arterra Bioscience SpA's gross margin of last year was 0.8746705.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Arterra Bioscience SpA's asset turnover of this year was 0.351067. Arterra Bioscience SpA's asset turnover of last year was 0.33240401.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
0
+
1
+
0
+
1
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Arterra Bioscience SpA has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Arterra Bioscience SpA (MIL:ARBS) has a Piotroski F-Score of 7 as of Jul. 18, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Arterra Bioscience SpA and its competitors. This is near median its historical median of 7.00. Over the past decade, Arterra Bioscience SpA's Piotroski F-Score has ranged from 5.00 to 8.00. According to the industry distribution chart, Arterra Bioscience SpA ranks #42 out of 1333 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Arterra Bioscience SpA's Piotroski F-Score too high?
Arterra Bioscience SpA's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Arterra Bioscience SpA's value of 7 is 133.3% above this industry median. Based on the distribution chart, Arterra Bioscience SpA ranks #42 out of 1333 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arterra Bioscience SpA ranks #42 out of 1333 companies for Piotroski F-Score. This places Arterra Bioscience SpA in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Arterra Bioscience SpA's value of 7 is 133.3% above this benchmark. Historically, Arterra Bioscience SpA's own Piotroski F-Score has ranged from 5.00 to 8.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 3.00, Arterra Bioscience SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arterra Bioscience SpA's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Arterra Bioscience SpA and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arterra Bioscience SpA's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 133.3% above the Biotechnology industry median of 3.00. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current Piotroski F-Score is 7 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?
Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued.
The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91.
GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.
Key valuation signals for MIL:ARBS:
Piotroski F-Score: 7 (near median its 10-year median of 7.00)
GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
Industry Position: 133.3% above the Biotechnology median (#42 of 1333)
No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score
Get the complete analysis for MIL:ARBS
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:ARBS has been successfully added to your 
